GAITHERSBURG, Md., Nov. 18, 2022 /PRNewswire/ -- Novavax, Inc. (NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, ...

Novavax’s alliance with Sanofi came at an opportune time for the beleaguered vaccine developer. Its protein-based Covid-19 vaccine never reached the revenue highs achieved by the messenger RNA ...

It can take a long time to create a new vaccine and at the same time, there have been many evolutions and new strains of the ...

Shah Capital increased its stake to about 8.3% and said the gap between Novavax’s scientific potential and its commercial ...

The Food and Drug Administration (FDA) signed off Wednesday on an emergency use authorization for the Novavax COVID-19 vaccine for individuals 18 years of age and older. The Novavax vaccine is protein ...

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. American adults who haven't yet gotten vaccinated against COVID-19 should consider a new option ...

NEW YORK -- The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended ...

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Novavax ( (NVAX)) has issued an update.

How the United States' potential fourth vaccine stacks up against existing ones. Maryland-based biotech company Novavax said Monday that its COVID-19 vaccine was shown to be highly effective in ...

Novavax, Inc. (NASDAQ:NVAX) on Thursday revealed preclinical data from the H5N1 avian pandemic influenza vaccine candidate. Leveraging Novavax’s recombinant, protein-based nanoparticle technology and ...